Inovio Pharmaceuticals (INO) Stock: Buy, Sell, or Hold?
INO - Inovio Pharmaceuticals, Inc.
$1.25
-0.03 (-2.34%)
âŧ
5d:
-8.09%
30d:
+62.34%
90d:
+13.64%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When INO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: INO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: INO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: INO is currently trading at $1.25, which is considered slightly high relative to its 30-day fair value range of $0.84 to $1.37.
Technical Outlook: Technically, INO is in a downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INO scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+153.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INO is in a downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INO scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.17 (+153.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.84 -
$1.37
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.3% below Wall St target ($3.17)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.84 -
$1.37
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.22
Resistance Level
$1.45
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.84
Wall Street Target
$3.17
(+153.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 13, 2026 11:18 AM ET
Data refreshes hourly during market hours. Next update: 12:18 PM
Data refreshes hourly during market hours. Next update: 12:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$137 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
